This content is machine translated Hematology and oncology The one-size-fits-all approach is history, personalized medicine is the future The pursuit of individuality was the focus of this year’s Congress of Oncology and Hematology in Switzerland. This paradigm shift is set to change patients’ lives and redefine cancer treatment.…
View Post 4 min This content is machine translated Immuno-oncological therapies CAR-T cell therapy for hematologic cancers Immunotherapies are now established pillars in the treatment of cancer. The principle of CAR-T cell therapy is that the body’s own T cells are programmed to destroy cancer cells through…
View Post 7 min This content is machine translated Hematology Blood, blood cells, blood diseases – current research at a glance The most important European meeting of hematologists is held annually in June. Renowned experts will gather at the EHA Annual Congress to present and discuss current research data on various…
View Post 8 min This content is machine translated Hematology Leukemia, malignancy and co. on the test bench The annual meeting of the American Society of Hematology (ASH) is considered the most important congress on hematologic diseases worldwide. International experts again exchanged information on current research results and…
View Post 5 min This content is machine translated Chronic lymphocytic leukemia BTK inhibitors and other hopefuls The therapy of chronic lymphocytic leukemia (CLL) is currently undergoing rapid change. Increasingly, chemoimmunotherapy, which has been commonly used in the past, is being replaced by more targeted treatments. In…
View Post 3 min This content is machine translated Hematologic malignancies Lymphocytic lymphomas and leukemias: focus on current therapies Malignant hematologic diseases such as leukemias or lymphomas represent the fourth most common cancer and affect approximately 20/100,000 population per year in Europe. A number of effective substances are now…
View Post 2 min This content is machine translated Chronic myeloid leukemia In the long term: first-line therapy with TKI convinces with efficacy Chronic myeloid leukemia is a malignant disease of the bone marrow in which too many white blood cells are produced. In most patients, a genetic alteration of the Philadelphia chromosome…
View Post 2 min This content is machine translated BCL-2 Inhibition The next chapter in blood cancer therapy is opened BCL-2 inhibition represents a milestone in the history of blood cancer treatment. Approved for the treatment of relapsed or refractory chronic lymphocytic leukemia (CLL), oral small molecule is now also…
View Post 2 min This content is machine translated CAR-T cells Focus on innovative cancer therapy CAR-T cells are currently one of the most exciting developments in immunotherapy. It combines immunotherapy, cell therapy and gene therapy and could become a routine treatment in the future.
View Post 4 min This content is machine translated DKK in Berlin - Leukemia treatment Revolution through personalized therapy Knowledge of molecular markers in leukemias could help identify high-risk patients in the future. In addition, there is an opportunity to develop further targeted therapeutic approaches. Some already approved therapeutics…
View Post 4 min This content is machine translated Breast cancer/lung cancer/leukemia Targeted Therapy At the beginning of August, a press roundtable on the specialist field of oncology was held in Zurich. Insight was provided into “targeted therapy” in breast carcinoma, acute lymphoblastic leukemia…
